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Chronic fatigue syndrome (CFS) is one of a
group of unexplained illnesses, including
fibromyalgia (FM) and irritable bowel syn-
drome (IBS), whose diagnosis depends on the
specialty of the physician to whom the
patient turns for help. When evaluated for
these unexplained illnesses, the CFS patient
often fulfills case definitions for other unex-
plained illnesses as well (1). This overlap has
led some investigators to propose that these
functional somatic illnesses are variants of one
another with little need to identify and label
them individually (2). However, the clinical
similarity of these illnesses does not necessar-
ily mean that they each have the same cause.
For example, patients with diffuse pain may
sleep poorly and thus develop fatigue,
whereas people who have disturbed sleep and
inactivity may develop diffuse pain (3). If
patients with CFS and FM were drawn from
the same general population, one would not
expect to ﬁnd differences between these two
patient subgroups. That in fact is not the
case. We have found that patients with CFS
have less functional impairment than those
with both CFS and FM (4).
Because the diagnosis of FM carries impli-
cations as to the clinical status of a CFS
patient, we believe it continues to make sense
to try to diagnose each of these medically
unexplained illnesses. Because there is no
objective biomedical marker for CFS, the diag-
nosis is based on clinical case deﬁnitions. The
case deﬁnitions for the diagnosis of CFS (5,6)
grew out of the fact that severe fatigue and ﬂu-
like symptoms—often beginning suddenly—
were thought to reflect underlying viral
infection. Thus, the diagnostic criteria for CFS
are fulfilled when a patient has at least 6
months of new-onset, medically unexplained
fatigue accompanied by at least four of eight
identified infectious, rheumatological, and
neuropsychiatric symptoms. The illness is
common, appearing in more than 0.4% of the
population (7), with a male-to-female ratio of
approximately 1 to 4, and is often disabling;
patients with CFS report debility worse than a
similar demographic sample of patients with
congestive heart failure (8).
Infectious and Immunologic
Factors
The early idea that CFS represented a form of
chronic Epstein-Barr infection was quickly
dropped when data were reported indicating
that elevated Epstein-Barr virus titers, reﬂect-
ing prior infection, are not uncommon in
healthy people (9). Reports on the possibility
of the illness being caused by chronic infec-
tion by other agents, including enteroviruses
(10), human herpesvirus 6 (11), Mycoplasma
(12), retroviruses (13), Borna disease virus
(14), parvovirus B19 (15), and “stealth”
viruses (16), continue to appear, but confir-
mation and replication are lacking (17–20).
Infection can certainly trigger the onset of
CFS, and patients reporting a sudden, viral-
like onset to their illness report this occurring
in winter months (21). Elevated rates of a
CFS-like illness are known to follow infec-
tious mononucleosis (22), Lyme disease (23),
and severe viral infection (24). Thus, post-
infectious fatigue exists, but persistence of an
infectious agent has not been demonstrated.
Obviously covert infections such as chronic
sinusitis warrant careful consideration and, if
diagnosed, require adequate treatment.
Patients do complain of sensitivity to fre-
quent upper respiratory infections, but it is
not clear if these really do reﬂect infection or
instead represent allergic or nonallergic
rhinitis. These two symptom-producing con-
ditions are very common in CFS—occurring,
respectively, in 30% and 46% of CFS
patients (25).
If persistent infection is not the cause,
another hypothesis is that CFS is infection-
triggered immunologic activation or dysregu-
lation. A number of papers have reported
immune activation in CFS [for review, see
(26,27)]. The critical research issue is to
determine if these changes are the conse-
quence of an underlying etiological mecha-
nism producing the symptoms of CFS or,
instead, occur because of secondary psy-
chophysiological changes wrought by the dis-
ease, such as inactivity, disturbed sleep,
and/or chronic stress. When we matched our
CFS group with controls who, like the
patients, were sedentary, we could find no
evidence of immunologic dysfunction in the
patient group (28). Interestingly, some differ-
ences did emerge in a group of Gulf War vet-
erans (GVs) who developed CFS in a
quasi-epidemic pattern; we think we were
able to ﬁnd these differences because the vet-
erans as a group were immunologically more
homogeneous than the civilians as a group.
Despite our inability to find specific
cytokine or cell-surface-marker abnormalities
in nonveteran CFS patients, other data do
support some underlying immunologic prob-
lem: a) some CFS patients appear to have an
antibody against a specific nuclear antigen
(29), b) patients have a dysregulated 2,5-A/
RNase L antiviral defense pathway (30,31),
and c) treatment with an immune-active
agent, mismatched RNA, may reduce dis-
ability (32) (a study to replicate this outcome
is currently under way).
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Unexplained Symptoms
Medical history has shown that clinical disease entities or syndromes are composed of many sub-
groups—each with its own cause and pathogenesis. Although we cannot be sure, we expect the
same outcome for chronic fatigue syndrome (CFS), a medically unexplained condition character-
ized by disabling fatigue accompanied by infectious, rheumatological, and neuropsychiatric symp-
toms. Although the ailment clearly can occur after severe infection, no convincing data exist to
support an infectious (or immunologic) process in disease maintenance. Instead, data point to sev-
eral possible pathophysiological processes: a covert encephalopathy, impaired physiological capa-
bility to respond to physical and mental stressors, and psychological factors related to concerns
about effort exacerbating symptoms. Each of these is under intense investigation. In addition,
some data do exist to indicate that environmental agents also can elicit a state of chronic fatigue.
We expect data to accumulate to support the belief that CFS has multiple causes. Key words:
brain, cardiovascular, chronic fatigue syndrome, cognition, immunologic, psychiatric, viral.
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Psychiatric Factors
A very different set of hypotheses considers
CFS a variant of major depressive disorder or
simply a manifestation of somatization disor-
der (SD). Regarding major depressive disor-
der, CFS patients—even those with
concurrent major depression—are phenome-
nologically different from patients with major
depression alone. CFS patients have less self-
reproach and more somatic symptoms than
depressed patients (33) [i.e., the cognitive
styles of CFS and major depression differ
(34)], less disturbed personalities (35), and a
different immunologic profile (36).
Determining whether CFS is a manifestation
of SD is a harder question. There is no doubt
that CFS is the modern equivalent of neuras-
thenia (37). But that observation leaves the
question: What is neurasthenia?
The diagnosis of SD depends on the
beliefs of the medical evaluator and the diag-
nostic assessment tool used. If the evaluator
applies the subsyndromal diagnostic criteria
of Escobar et al. (38) and reflects the belief
that CFS symptoms are of a psychiatric
nature, then nearly every CFS patient will be
shown to have SD. However, if the CFS
symptoms are coded as physical and strict
Diagnostic Manual of Mental and Behavioral
Disorders-III-R criteria are applied, only 2.3%
of patients have SD (39).
Just because it is not clear how to diag-
nose SD in CFS patients does not mean that
CFS patients do not have this disorder. An
Australian group (40) using factor analysis of
symptom self-report data found that 22% of
CFS patients reported a large number of
somatic symptoms. This group of patients
had a high probability of having concurrent
psychiatric disorder. They were labeled “som-
atizers.” The remaining patients in this study
had fewer somatic symptoms and less psycho-
pathology. Similar results led American
researchers to suggest that the case deﬁnition
for CFS be changed so that the diagnosis
would be given only to those patients with
relatively few symptoms (41). This strategy
would exclude patients with possible SD.
Another approach might be to exclude
patients with a positive history for major psy-
chopathology beginning before CFS onset
and then to stratify on the basis of the exis-
tence of a current major psychiatric disorder;
this tactic would use the existence of psycho-
pathology as a marker of SD. To test if this
idea would work, we rank-ordered our
patients on the basis of their illness severity
ranging from category 1 to category 6 (42):
category 1 included patients fulfilling the
more rigorous 1988 case deﬁnition (5) as well
as reporting symptom intensities of ≥ 3 on
0–5 severity scales; categories 2–5 were pro-
gressively less severe rankings. Category 6
included patients who fulﬁlled the 1994 but
not the 1998 case definition and had symp-
tom severities < 3. CFS severity in those with
Axis I co-morbidity (n = 19) tended to be
higher (median [M] = 1) than in those with-
out comorbidity (n = 48; M = 2; p < 0.14).
However, the difference in symptom severity
between the groups was small. This result
means that practitioners cannot assume SD in
patients with psychiatric comorbidity.
However, they should look for this comor-
bidity and treat it when it exists.
In contrast to efforts to predict or identify
somatization, we have arrived at a concrete
marker of increased risk for major psycho-
pathology (4). This occurs when patients
have multiple medically unexplained syn-
dromes. In evaluating our patients, each
receives a standardized psychiatric diagnostic
interview as well as assessments for FM or for
IBS. The prevalence of lifetime major depres-
sion was 36% of 31 patients with CFS alone,
57% of 28 patients with both CFS and FM,
and 73% of 22 patients with CFS, FM, and
IBS (χ2 = 7.45; p < 0.05). We interpret these
results to mean that patients bearing three
concurrent medically unexplained syndromes
(multiple chemical sensitivity can be substi-
tuted for IBS) may be considered to have
psychopathology and should routinely be sent
for psychological or psychiatric evaluation
and possible treatment. It will be very impor-
tant for future research studies to provide
information on the constitution of their sub-
jects. Obviously, if study samples are skewed
toward groups having multiple concurrent
medically unexplained syndromes, this could
result in outcomes that support psychiatric
factors in the genesis of CFS, whereas studies
of patients with CFS alone might be more
useful in efforts to identify biomedical
markers of the illness.
Behavioral Factors
The U.K. group in London that studies CFS
has focused on disease maintenance, and their
1998 book Chronic Fatigue and Its Syndromes
is good reading for those seeking detailed
information on CFS (43). Wessely et al.
believe that person factors interact with illness
triggers and subsequent deconditioning to
prolong illness duration. Thus, people with a
tendency for mood problems or ampliﬁcation
of somatic sensations might become worried
about activity-related symptoms after some
viral illness and thus reduce activity further.
They support this line of thinking with their
successful trials (44,45) of cognitive behav-
ioral therapy (CBT).
Although this model may explain contin-
ued illness in some CFS patients, it certainly
does not pertain to all CFS patients and is
thus not too satisfactory. In contrast to the
above scenario is the previously well patient
who presents to her doctor for the ﬁrst time
with an apparent flu of sudden onset that
never goes away and who continues her for-
mer life—albeit at reduced levels of activity.
When evaluated, such patients frequently do
not have the sort of negative person factors
and activity-related fears identified in the
U.K. researchers’ model.
The CBT story is also not clear-cut. The
success of CBT as a treatment points to a role
for person factors in the perception of symp-
tom severity, but one cannot make further
inferences about such factors in the genesis of
illness. This is because CBT is useful in treat-
ing any chronic illness—medical as well as psy-
chiatric. For example, CBT reduces symptom
severity in patients with known medical disease
such as rheumatoid arthritis (46). Inferring
that CFS is a psychogenic disorder because of
the success of CBT is risky for a second reason,
as well: Not all CBT trials are effective in
relieving the symptoms of CFS (47). Friedberg
and Krupp suggest that CBT did not help
their patients because they were not too dis-
abled by their illness. Indeed, in trying to
understand CFS, it would make sense to focus
on the higher functioning patients—those who
have fewer problems with secondary factors
produced by the illness such as poor sleep,
inactivity, and chronic stress.
Orthostatic Intolerance
Another hypothesis for illness maintenance
has to do with cardiovascular abnormalities
and the patient complaint of feeling much
worse while standing. A report from Johns
Hopkins indicated that a majority of CFS
patients developed delayed orthostatic
hypotension and that symptoms disappeared
after treatment using either volume expansion
or beta blockers (48). However, we found no
difference in orthostatic intolerance between
unmedicated CFS patients (i.e., not even tak-
ing low doses of tricyclic antidepressants) and
sedentary healthy controls (49). Using a non-
invasive technique called impedance cardiog-
raphy, we did, however, ﬁnd the CFS group
to have lower stroke volumes, even in baseline
conditions. Whether this ﬁnding indicates a
covert cardiac problem or one secondary to
reduced blood volume remains a research
question; both of these have been suggested
(50,51). We have repeated our studies of car-
diac stroke volume and have found it to be
lowest in patients with the most severe symp-
toms (52). This result does suggest that low
cardiac output could be playing a role in the
genesis of postexertional fatigue, a common
complaint in CFS patients. We are currently
extending these studies to tests of cardiac func-
tion using standard clinical radioisotope tech-
niques (i.e., multiple gated acquisition scans).
Our data indicate that tilt testing is not a
sensitive way to diagnose orthostatic intoler-
ance in CFS, with two provisos. First, it is
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reasonable for the physician to monitor heart
rate and blood pressure after 5 min of supine
rest and then every minute for 5 min of stand-
ing. Some patients may show a dramatic pos-
tural tachycardia (53) or other orthostatic
change (54) within this brief time frame.
When present, these should be treated.
Second, tilt may be a better diagnostic tool for
children than for adults. A recent controlled
study showed adolescents with CFS to be
highly sensitive to orthostatic challenge (55).
Finally, data do exist to suggest that a
risk factor for developing CFS may be
impaired work capacity. Individuals who
develop chronic fatigue after infectious
mononucleosis tend to be those with lower
physical fitness (56). A number of studies
have evaluated fitness by using exercise
treadmill testing. One early study suggested
that CFS patients were less fit (perhaps
deconditioned) relative to healthy controls
(57). Although this study was flawed in its
not using sedentary healthy people as con-
trols, two other studies controlled for the
inactivity in patients and still found the
same result (58,59). Data from another
study suggested that subtle reductions in
blood volume might have been responsible
for the reduced peak oxygen consumption
found (60). Inbar et al. (59) found an unex-
pectedly slow increase in heart rate and
lower peak heart rate values in controls,
leading them to conclude that these ﬁndings
were not consistent with deconditioning in
CFS. In contrast to reports suggesting
impaired work capacity in CFS, a number of
other groups (61,62), including our own
(63), have not been able to confirm differ-
ences in work capacity between CFS patients
and controls. Of great interest are data from
the Seattle CFS twin study (64). They also
showed no significant difference in indices
of fitness or work capacity between healthy
twins and twins with CFS. However, the
study found both sets of twins to have
extremely low VO2 maximum values after
exercise (64). This suggests that impaired
metabolic capacity to respond to exercise
may be a risk factor for developing CFS.
Inbar et al. (59) noted a hypodynamic
cardiac response in terms of heart rate exer-
cise. They concluded that this may be “a dis-
ease-specific physiological attribute, leading
to low cardiac output and early onset of
fatigue” with reduced exercise capacity. We
have found a similar hypodynamic response
of the endocrine system to exercise challenge
(65) and of the cardiovascular system to a
stressful cognitive probe (66). In fact, we
found that those patients who showed the
lowest blood pressure response to the stressor
reported the most severe symptoms. These
data support a role for these physiological sys-
tems in producing the common patient
complaint of symptoms worsening after both
physical and mental stressors.
Covert Encephalopathy
One of the most common complaints of CFS
patients are difficulties paying attention to
and memorizing new information. Although
some groups have shown that objective cogni-
tive difficulties exist, particularly in the
encoding of information, others have not
found evidence of cognitive dysfunction in
patients with CFS [for review, see Tiersky
et al. (67)]. The major focus of our own work
evaluates the possibility that some CFS
patients have a mild encephalopathy associ-
ated with their illness. Initially, we found that
CFS patients had signiﬁcant cognitive abnor-
malities (68). We repeated our studies after
stratifying patients based on the presence or
absence of major psychiatric diagnosis begin-
ning after CFS onset. The group with no psy-
chiatric diagnoses was the one with the most
cognitive dysfunction (69). Next, we showed
that these cognitive abnormalities correlated
with functional status in that the more cogni-
tive the impairment, the more the patient
reported cutting down on her normal activi-
ties (70). Then we did a study in which two
neuroradiologists, blinded to group, evaluated
the brain magnetic resonance images (MRIs)
of CFS patients and controls (71). Our a pri-
ori hypothesis that CFS patients with no
major psychiatric disorders would have the
most abnormalities was confirmed: 66% of
that group had abnormalities in contrast to
30% of the group with major psychiatric
diagnoses and 22% of the control group. The
abnormalities found were subtle, most com-
monly small T2-weighted lesions (version of
MRI that shows lesions containing water) in
frontal lobes. Finally, we asked whether the
presence of an abnormality had any conse-
quences on functional status. If these lesions
were simply epiphenomena of the illness, we
would expect no relation. But if the lesions
were involved in the pathogenetic process, a
relation might emerge. We found that the
group with abnormalities reported signifi-
cantly poorer physical functioning on the
Short Form-36 (SF-36), a common disability
assessment tool (72). Although in this study
we found the presence of small lesions in the
group of CFS patients who also showed the
most cognitive impairment in related studies
(69), the low number of lesions present made
it difficult to explain the cognitive dysfunc-
tion measured. Therefore, we next quantita-
tively assessed cerebral ventricular volumes in
CFS patients to get a more subtle indication
of brain involvement. The results of a pilot
study suggested that ventricular volumes in
CFS patients may be larger than those in
healthy controls (73), a ﬁnding that currently
awaits further conﬁrmation.
In a set of studies trying to link cognitive
function with underlying brain function, we
conducted a set of functional magnetic reso-
nance imaging studies and found that CFS
patients had more diffuse activation in the
posterior regions of the brain than did
healthy controls. Based on other studies, this
pattern of activation indicates that cognitive
work may be more effortful for CFS
patients—a finding that one might expect
with subtle brain disease. Our interpretation
of all these data is that some CFS patients
may have a subtle brain problem.
Environmental Causes
Behan (74) has noted that some patients with
well-documented chronic exposure to
organophosphates develop a syndrome that
sounds very much like CFS, and cases of CFS
have been reported to follow ciguatera poi-
soning and exposure to solvents (75).
Supporting the idea that environmental cont-
aminants are associated with CFS is an
unreplicated report of increased organochlo-
rine levels in patients with CFS (76).
The biggest drive to the hypothesis that
toxic chemicals could cause CFS is an out-
growth of the Gulf War. Nearly 10% of
deployed American troops returned home
with a host of medically unexplained symp-
toms—primarily fatigue, musculoskeletal
achiness, and cognitive dysfunction. In a sur-
vey of healthcare-seeking GVs, we found that
16.1% reported symptoms consistent with
CFS (77) and that, on careful clinical evalua-
tion, many fulﬁlled the published case deﬁni-
tion for CFS (42); ﬁnding CFS as a common
diagnosis in symptomatic GVs has been
reported by others, as well (78). The problem
with linking toxic factors with CFS is that
veterans did not suffer symptoms of acute
exposure to such factors. Despite this lack of
symptoms, veterans did have exposures.
Nearly all GVs used insecticides, some took
pyridostigmine bromide as an antidote to
possible nerve gas exposure, and some were
probably exposed to subclinical doses of
Sarin, one of the most toxic nerve gases that
exists. Although the common belief was that
individuals had to have had acute symptoms
of intoxication in order to evince chronic
symptoms, more recent evidence does sug-
gest that symptoms can develop in individu-
als who do not report definite episodes of
acute toxicity (79,80).
Although one group did publish data
suggesting that there were discrete Gulf War
syndromes (81)—some of which correlated
with different exposures (82), no other group
has been able to replicate this result. To the
contrary, available data indicate that there is
no unique constellation of symptoms related
to participation in the Persian Gulf conflict
(83,84). Of great interest, however, is the
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probability of receiving multiple vaccinations
while at the Persian Gulf than did healthy
GVs (85).
The symptom complex found in GVs
occurs in veterans deployed to theaters out-
side the Persian Gulf (86) as well as in non-
deployed veterans (84). The fact that CFS is
thought to occur relatively frequently in over-
seas development workers (87) does raise the
possibility of another common variable
occurring during deployment and conﬂict—
stress. Supporting a role of possible stress in
the genesis of the GVs’ medically unexplained
fatigue is a 50% rate of post-traumatic stress
disorder (PTSD) in 76 GVs with CFS or its
less severe counterpart, idiopathic chronic
fatigue (ICF) (88); in contrast, PTSD occurs
in only about 1% of nonveteran CFS
patients. However, stress is no less benign
than toxic exposures; veterans with PTSD are
known to suffer significant hippocampal
neuronal loss (89).
Although epidemiologic evidence does
not support the idea of a unique Gulf War
syndrome, data do exist to support the infer-
ence that service in the Persian Gulf has
pathological consequences: a) GVs with
CFS/ICF have objectively measured cogni-
tive impairment (90); b) one study reported
that GVs have abnormal peripheral nerve
function compared with civilian controls
(91), and our own work noted elevated
thresholds to fine touch but not to heat in
GVs with CFS/ICF compared with healthy
GVs—of great interest was the finding that
the healthy GV group had elevated thresh-
olds relative to those of a civilian control
group (92); and c) a number of abnormalities
of central nervous system origin have been
found in symptomatic GVs (93).
Assuming that large numbers of GVs
experienced both stress and/or potential toxic
exposures, the question that immediately
comes up is why only 10% of the entire
group developed symptoms. One group has
done some genetic testing and has found sig-
nificant decreases in one specific arylesterase
in sick GVs compared with healthy GVs.
This enzyme system is involved in destroying
via hydrolysis organophosphate anticholin-
esterase poisons (94). Because the decrease in
this enzyme was only one of several statistical
comparisons made, the possibility of a type 1
statistical error existing (i.e., the finding
occurred simply by chance) is a real one.
However, we have analyzed plasma samples
and have been able to replicate this finding:
symptomatic GVs with abnormal neuro-
psychological test results have significantly
lower levels of this enzyme than either sympto-
matic GVs with normal neuropsychological
test results or healthy GVs (95).
CFS Research in the
Twenty-First Century
To summarize, CFS is a clinical disease entity
with no lab test to corroborate diagnosis.
Thus, like other syndromes, it probably is het-
erogeneous, with several different pathogenetic
paths leading to the same end result—the
patient with severe fatigue and other constitu-
tional symptoms. Initial focus on discrete viral
and immunologic causes continues but is on
the wane. Table 1 shows the demographic
composition of the 203 CFS patients who had
no major psychopathology in the 5 years
before the onset of their CFS whom we have
studied in our center over the past 8 years.
Without a doubt, some have SD, but how
does a physician identify those patients? In
contrast, some patients have low cardiac stroke
volumes and others have the suggestion of a
mild encephalopathy. Our plan is to determine
if subsets of CFS patients have identifiable
medical causes that will ultimately be treatable.
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